home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409c.zip
/
M9490481.TXT
< prev
next >
Wrap
Text File
|
1994-09-19
|
2KB
|
34 lines
Document 0481
DOCN M9490481
TI Use of pentoxifylline therapy for patients with AIDS-related wasting:
pilot study.
DT 9411
AU Landman D; Sarai A; Sathe SS; Department of Medicine, Department of
Veterans Affairs Medical; Center, Brooklyn, New York 11209.
SO Clin Infect Dis. 1994 Jan;18(1):97-9. Unique Identifier : AIDSLINE
MED/94331513
AB Severe weight loss is a common manifestation of advanced infection with
the human immunodeficiency virus. The level of tumor necrosis factor
alpha (TNF-alpha), an inducer of cachexia in laboratory animals, is
elevated in the serum of some patients with AIDS. In a pilot study, five
patients with unexplained AIDS-related wasting were treated with
pentoxifylline, a known suppressor of TNF-alpha production. Three of the
five patients had elevated baseline serum levels of TNF-alpha, and these
three patients did not have significant weight gain after 4-8 weeks of
pentoxifylline therapy despite the reduction of serum TNF-alpha levels.
The remaining two patients, who did not have elevated serum levels of
TNF-alpha, continued to lose weight and developed extensive bacterial
pneumonia within 3 weeks of starting pentoxifylline therapy. Thus,
therapy with pentoxifylline did not clearly benefit the patients with
AIDS-related wasting in this uncontrolled pilot study; indeed, it might
have been harmful for a subgroup of these patients.
DE Acquired Immunodeficiency Syndrome/BLOOD/*COMPLICATIONS/MORTALITY Adult
Cachexia/BLOOD/*DRUG THERAPY/MORTALITY Human Male Middle Age
Pentoxifylline/ADVERSE EFFECTS/*THERAPEUTIC USE Pilot Projects
Prognosis Tumor Necrosis Factor/*ANALYSIS Weight Loss/*DRUG EFFECTS
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).